HealthSignals coverage organized by therapeutic area: oncology, cardio-metabolic disease, rare and genetic diseases, neuroscience, immunology and infectious diseases across Latin America and the United States.
HealthSignals coverage organized by therapeutic area: oncology, cardio-metabolic disease, rare and genetic diseases, neuroscience, immunology and infectious diseases across Latin America and the United States.
AbbVie has completed its $10.9 billion acquisition of Apogee Therapeutics, adding zumilokibart — a long-acting interleukin-13 antibody positioned against Dupixent — to its immunology portfolio.
Eli Lilly agreed to acquire Merida Biosciences for up to $2.9 billion, adding a precision antibody-targeting platform to its immunology pipeline as the company’s 2026 acquisition total surpasses $31 billion.
Colombia’s Ministry of Health declared public interest grounds to pursue mandatory licensing of Gilead’s sofosbuvir-based hepatitis C patents, transferring the process to the competition authority for a final determination.
Anvisa cancelled Elevidys’s conditional registration on August 24 at Roche’s request, citing insufficient safety and efficacy data — ending Brazilian access to the country’s most expensive approved drug.
The FDA has approved Revolution Medicines’ daraxonrasib (Rasonque) for metastatic pancreatic adenocarcinoma, after a phase III trial of 500 patients showed median overall survival of 13.2 months versus 6.7 months …
Anvisa has approved datopotamab deruxtecan (Datroway) for adults with advanced EGFR-mutated non-small cell lung cancer in Brazil, expanding targeted therapy options in one of oncology’s most active segments.
Positive Phase 2b results for elecoglipron and aleniglipron confirm that small-molecule oral GLP-1 receptor agonists can deliver meaningful weight loss without food or fluid restrictions, intensifying competition in obesity and …
CVS Caremark will cover Eli Lilly’s oral GLP-1 pill Foundayo from June 1 and restore Zepbound as a preferred option by October 1, completing Lilly’s access across all three major …
Anvisa has granted Eurofarma the first generic registration for the dapagliflozin-metformin fixed-dose combination, mandating a minimum 35% price discount versus AstraZeneca’s Xigduo XR under Generic Law 9.787/1999.
ANS has added a PARP inhibitor for BRCA1/2-positive metastatic castration-resistant prostate cancer to Brazil’s mandatory private insurance coverage list, effective July 1, 2026, following public consultation.
You must be logged in to post a comment.